Lincoln Diagnostics (U.S.), Omega Diagnostics (U.K.), Siemens Healthcare (Germany), Stallergenes (France), and Thermo Fisher Scientific (U.S)
(PRWEB) February 07, 2015
The global allergy diagnostics market is valued at $1,228.58 million in 2014 and poised to grow at a CAGR of 12.67% between 2014 and 2019 to reach $2,230.72 million in 2019. The consumables product segment is expected to grow at the highest CAGR between 2014 and 2019. Reagents and antibodies are major components of consumables used to detect allergens and drive the consumable segment for allergy diagnostics market. Enzyme-linked immunosorbent assays (ELISA) is the most important and preferred in vitro test for detection of allergies. The accuracy, reproducibility and ease of use of ELISA are resulting in high adoption of the ELISA technology in diagnostic laboratories and hospitals sector as well as the industries sector.
The incidence of allergic diseases is increasingly rapidly across the globe. According to the World Health Organization (WHO), about 300 million asthma cases were recorded globally in 2013 and are expected to increase to 400 million by 2025. Furthermore, in 2013, about 400 million people suffered from allergic rhinitis and about one-tenth of the population suffered from drug allergies. Increasing global incidence of allergic diseases has increased the use of diagnostic tests for allergy, which is expected to drive the growth of assay kits and consumables product segment.
North America is expected to account for the largest share of the global allergy diagnostics market in 2014. However Asia is expected to grow at the highest CAGR in the forecast period and represents a new revenue pocket for the allergy diagnostics market. This region is expected to witness a steady year-on-year growth due to to rapid economic and industrial development and reliance on fossil fuels for energy. In 2012 Asia contributed to over 50% of the worldwide carbon dioxide emissions due to rapid economic and industrial development. Increased pollution due to growing use of fossil fuel is an important causative factor for allergic diseases. This will be an important driver for the allergy diagnostics market in this geographic segment. Moreover rise in incidence of allergic diseases and increase in healthcare expenditure in this region will further fuel the demand for allergy diagnostic products.
For Report Inquiry @ http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=232871701
New product launches and expansions were the two most important growth strategies employed in this market. An analysis of market developments between 2010 and 2014 revealed that new products launches was the most adopted growth strategy employed by the market leaders in this period. This strategy was adopted by Thermo Fisher Scientific (U.S.) and Lincoln Diagnostics (U.S.).
Expansions are another important growth strategy adopted by players in this market to gain immediate technological competency and strengthen geographic presence. This strategy was adopted by very few players in this market, which are Hitachi Chemical Diagnostics (U.S.), Hycor Biomedical (China), Stallergenes (France), and Thermo Fisher Scientific (U.S.).
Ask for PDF Manual @ http://www.marketsandmarkets.com/pdfdownload.asp?id=232871701
There is a high degree of consolidation in the allergy diagnostics market, with few large players dominating the market. Stringent regulatory requirements and a high degree of consolidation are major barriers for new entrants in this market. Some important acquisitions in this market include the acquisitions of Phadia in 2011 and Life Technologies in 2014 by Thermo Fisher Scientific, Alergo Pharma in 2014 by Stallergenes, and that of Beckman Coulter in 2011 by Danaher Corporation.
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.
M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas, TX 75252
Visit MarketsandMarkets Blog@ http://mnmblog.org/market-research/healthcare/medical-devices